Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intermediate Phenotype and Genetic Mechanisms for Psychosis and Cognitive Disturbance in 22q11.2-Hemideletion Syndrome

NCT00105274 is registered in ClinicalTrials.gov with National Institute of Mental Health (NIMH) as lead sponsor.

NCT NCT00105274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00105274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intermediate Phenotype and Genetic Mechanisms for Psychosis and Cognitive Disturbance in 22q11.2-Hemideletion Syndrome
Lead sponsor
National Institute of Mental Health (NIMH)
Phase
Observational
Overall status
Completed
Start date
March 7, 2005
Completion date
February 2, 2010
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

22q11.2 syndrome, digeorge syndrome, velocardiofacial syndrome